Reversible inhibiting thromboxane A2 blocker utilisation for activity inhibition - by prolonging function and storage stability of thrombocytes in thrombocyte concentrates or preserved blood, for inhibiting aggregation and treating thrombosis

摘要

The utilisation comprises prolonging the activity and storage stability of thrombocytes in thrombocyte concentrates or preserved blood. The TXA2 blocker is pref. a TXA2 receptor agonist or a TXA synthetase inhibitor or has both activities. Esp. the TXA2 blocker is Sultroban or Daltroban. Sultroban is used in an amt. of more than 8 mg, (10-15 mg) in 400 ml thrombocyte concn. Daltroban is used in an amt. of more than 0.8 mg (1-1.5 mg) in 400 ml thrombocyte concn. USE/ADVANTAGE - The thromboxan TXA2 blockers have an anti aggregatory effect (i.e. avoid promoting activation processes in the thrombocytes in the concn. which may lead to aggregation). The effect in reversible (i.e. removed as soon as the thrombocytes are transferred to the patient, or the thrombocytes may not promote haemostasis). The activity of the TXA2 blockers is selective and undesired side effects are avoided. The addn. of the TXA2 blockers may be varied i.e. may be added to the finished thrombocyte, or during blood donation before leading the blood to the cyta phoresis device or used to treat the thombocyte donor prior to thrombocytapoeisis. The treated thrombocyte concentrates may be used to treat e.g. thrombocytoperic disorders